This notion is supported by the report by Hulstein et al. [27] that a nanobody made against the VWF A1 detected a very small amount of VWF in blood samples from healthy subjects, but a significantly increased amount of VWF in patients with TTP. This evidence concerns the gene VWF and thrombotic thrombocytopenic purpura.